Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 3:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "gene therapy" Clear all
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)

NCT06152237
View directory record Official record
Conditions
Rett Syndrome
Interventions
TSHA-102
Genetic
Lead sponsor
Taysha Gene Therapies, Inc.
Industry
Eligibility
5 Years to 8 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
3
States / cities
Chicago, Illinois • Saint Paul, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 24, 2026, 3:33 AM EDT
Completed Phase 2 Interventional

An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease

NCT00071877
View directory record Official record
Conditions
Fabry Disease
Interventions
Replagal
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 24, 2026, 3:33 AM EDT
Completed Phase 1Phase 2 Interventional

Gene Therapy for APOE4 Homozygote of Alzheimer's Disease

NCT03634007
View directory record Official record
Conditions
Alzheimer Disease, Early Onset Alzheimer Disease
Interventions
LX1001
Biological
Lead sponsor
Lexeo Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Maitland, Florida • Orlando, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jul 24, 2026, 3:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Vitamin B3 Derivative Nicotinamide Riboside (NR) in Bone, Skeletal Muscle and Metabolic Functions in Aging

NCT03818802
View directory record Official record
Conditions
Healthy Elderly Volunteers
Interventions
Nicotinamide Riboside, Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years to 80 Years · Female only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Jul 24, 2026, 3:33 AM EDT
Completed Early Phase 1 Interventional

TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia

NCT04518345
View directory record Official record
Conditions
Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
Interventions
Azacitidine, Dubermatinib
Drug
Lead sponsor
Uma Borate
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced Jul 24, 2026, 3:33 AM EDT
Terminated Phase 2 Interventional Results available

Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer

NCT00776295
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Jul 24, 2026, 3:33 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.

NCT06692712
View directory record Official record
Conditions
Hereditary Spastic Paraplegia Type 50
Interventions
MELPIDA
Genetic
Lead sponsor
Elpida Therapeutics SPC
Industry
Eligibility
4 Months to 72 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 24, 2026, 3:33 AM EDT
Active, not recruiting Phase 1 Interventional

Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease

NCT03664830
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Plerixafor
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 24, 2026, 3:33 AM EDT
Not listed Not applicable Interventional

Treatment Intensification for HIV Infected Patients With Multi-Drug Resistant Virus

NCT00102934
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide-intensified HAART
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2008 · Synced Jul 24, 2026, 3:33 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Mutations Associated With Parkinson s Disease

NCT01547832
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Jul 24, 2026, 3:33 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor

NCT03292458
View directory record Official record
Conditions
Spasmodic Dysphonia, Voice Tremor
Interventions
Sodium Oxybate
Drug
Lead sponsor
Kristina Simonyan
Other
Eligibility
21 Years to 80 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Jul 24, 2026, 3:33 AM EDT
Terminated Phase 1 Interventional

Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors

NCT00701298
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
peginterferon alfa-2b, decitabine, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 23, 2014 · Synced Jul 24, 2026, 3:33 AM EDT
Completed No phase listed Observational Results available

Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

NCT06680206
View directory record Official record
Conditions
Migraine
Interventions
Rimegepant, Triptans
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 24, 2026, 3:33 AM EDT
Not listed No phase listed Observational

Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission.

NCT00910884
View directory record Official record
Conditions
Breast Cancer
Interventions
laboratory biomarker analysis, therapeutic dietary intervention
Other · Procedure
Lead sponsor
Brabant Research
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Spokane Valley, Washington
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jul 24, 2026, 3:33 AM EDT
Completed Phase 3 Interventional

A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD

NCT00469352
View directory record Official record
Conditions
Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 21, 2011 · Synced Jul 24, 2026, 3:33 AM EDT
Completed Not applicable Interventional Results available

The Effect of Various Strength Training Protocols in ACL Reconstructed Participants

NCT03364647
View directory record Official record
Conditions
Anterior Cruciate Ligament (ACL) Tear, Physical Therapy
Interventions
Arm A - blood flow restriction training, Arm B - standard of care
Other
Lead sponsor
Brian W. Noehren
Other
Eligibility
15 Years to 40 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Jul 24, 2026, 3:33 AM EDT
Completed No phase listed Observational

Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer

NCT00516698
View directory record Official record
Conditions
Breast Cancer
Interventions
polymorphism analysis, high performance liquid chromatography, laboratory biomarker analysis, radiomammography
Genetic · Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
180
States / cities
Augusta, Georgia • Aurora, Illinois • Bloomington, Illinois + 111 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Jul 24, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

NCT01726738
View directory record Official record
Conditions
Stage III Melanoma, Stage IV Melanoma, Unresectable Melanoma, BRAF Mutant Melanoma
Interventions
BRAF inhibitor dabrafenib and MEK inhibitor trametinib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 24, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses

NCT04140292
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Photodynamic therapy (PDT), Vitamin D3
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Jul 24, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation

NCT00865904
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-809, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
18
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2015 · Synced Jul 24, 2026, 3:33 AM EDT
Active, not recruiting Not applicable Interventional

iAmHealthy Parents First: A Televideo Parent and Child Obesity Program for Rural Families

NCT05612971
View directory record Official record
Conditions
Weight Loss, Pediatric Obesity
Interventions
iAmHealthy Parents First, iAmHealthy
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
6 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jul 24, 2026, 3:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Suppression of Postprandial Monocyte Activation by Blueberries or Docosahexaenoic Acid in Humans

NCT02472171
View directory record Official record
Conditions
Inflammation
Interventions
High saturated fat meal, placebo powder and sunflower oil, High saturated fat meal, blueberry powder and sunflower oil, High saturated fat meal, placebo powder and DHA
Dietary Supplement
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
18 Years to 60 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Jul 24, 2026, 3:33 AM EDT
Completed No phase listed Observational Results available

Linking Endotypes and Outcomes in Pediatric Acute Respiratory Distress Syndrome

NCT04113434
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
44 Weeks to 17 Years
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
16
States / cities
Little Rock, Arkansas • Aurora, Colorado • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 24, 2026, 3:33 AM EDT
Completed Phase 1 Interventional

Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP)

NCT01711684
View directory record Official record
Conditions
Neoplasm Metastasis, Melanoma
Interventions
Diphenylcyclopropenone (DPCP)
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Jul 24, 2026, 3:33 AM EDT